Doctors are sounding the alarm about a small group of patients taking popular medications for weight loss and diabetes. Some have reported experiencing vision problems. However, so far, there is no clear evidence linking these issues directly to the drugs.
Patients using well-known medications like Ozempic, Wegovy, Mounjaro, and Zepbound have shown eye problems in recent studies. In one study, seven out of nine patients had reduced blood flow to the optic nerve, while one patient had inflammation in the optic nerve. Others reported blind spots or unusual symptoms.
The optic nerve plays a crucial role in vision. It sends signals from the eyes to the brain. When blood flow is compromised, it can lead to sudden and often lasting vision loss.
Most of the affected patients were adults in their 50s and 60s, suffering from diabetes or obesity, along with other heart-related issues that might also impact vision.
Dr. Norah Lincoff from the University of Buffalo is investigating whether these medications might pose a higher risk for vision loss. Their findings were published in JAMA Ophthalmology.
Previously, other studies have raised similar concerns. For instance, a July study from Mass Eye and Ear indicated that some patients prescribed semaglutide, a component in Ozempic and Wegovy, might be at increased risk of certain visual impairments.
Dr. Joseph Rizzo, an ophthalmologist at Mass General Brigham, emphasized that current findings are preliminary. He advised against abruptly stopping medications without consulting a doctor, suggesting instead a cautious approach in discussing treatment risks with patients.
While the medications have benefits, including improved blood sugar levels, researchers urge users to remain vigilant. A sudden dip or rise in blood sugar can also cause temporary vision changes, whether or not a patient is on these drugs.
Patients should consult their healthcare providers if they notice any changes in their vision while on these medications. Stopping or adjusting dosages should only be done under medical advice.
It’s important to note that drug manufacturers like Novo Nordisk, which produces Ozempic and Wegovy, have stated that loss of blood flow to the optic nerve is not listed as a known side effect according to their product labels. They assert that extensive studies do not indicate a causal link between their drugs and these vision issues.
As research continues, the focus remains on patient safety, and doctors are advised to refer any patients experiencing visual changes for immediate evaluation.
